| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10910843 | Lung Cancer | 2015 | 6 Pages |
Abstract
Icotinib with up to 400Â mg/day exhibited good tolerance and preliminary antitumor activity in Chinese NSCLC patients. Pharmacokinetics of icotinib and 5 major metabolites were fully investigated in NSCLC patients. Optimized biologic dose (OBD) was finally recommended to be 125Â mg t.i.d. for the later clinical study.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Dongyang Liu, Li Zhang, Yiwen Wu, Ji Jiang, Fenlai Tan, Yingxiang Wang, Yong Liu, Pei Hu,